LLY

993.83

+0.56%↑

JNJ

223.54

-1.04%↓

ABBV

204.83

-0.9%↓

UNH

367.65

+1.45%↑

AZN

184.96

+1.86%↑

LLY

993.83

+0.56%↑

JNJ

223.54

-1.04%↓

ABBV

204.83

-0.9%↓

UNH

367.65

+1.45%↑

AZN

184.96

+1.86%↑

LLY

993.83

+0.56%↑

JNJ

223.54

-1.04%↓

ABBV

204.83

-0.9%↓

UNH

367.65

+1.45%↑

AZN

184.96

+1.86%↑

LLY

993.83

+0.56%↑

JNJ

223.54

-1.04%↓

ABBV

204.83

-0.9%↓

UNH

367.65

+1.45%↑

AZN

184.96

+1.86%↑

LLY

993.83

+0.56%↑

JNJ

223.54

-1.04%↓

ABBV

204.83

-0.9%↓

UNH

367.65

+1.45%↑

AZN

184.96

+1.86%↑

Home・Listă Acțiuni・Fate Therapeutics Inc

Fate Therapeutics Inc

Deschisă

SectorSănătate

2.23 46.71

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.52

Maxim

2.38

Indicatori cheie
By Trading Economics
Venit	-124K -32M
Vânzări	-372K 1.4M
EPS	-0.27
Marjă de profit	-2,364.792
Angajați	161
EBITDA	-13M -42M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	+150% upside

Dividende
By Dow Jones
Următoarele câștiguri	11 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-22M 152M
Deschiderea anterioară	-44.48
Închiderea anterioară	2.23

Sentimentul știrilor

By Acuity

33%

67%

126 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

0.9101 / 1.14 Suport & Rezistență

Fate Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 mai 2026, 23:43 UTC

Evenimente importante

New Zealand's Unemployment Rate Falls in 1Q

5 mai 2026, 23:20 UTC

Acțiuni populare

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 mai 2026, 21:48 UTC

Câștiguri

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 mai 2026, 21:05 UTC

Achiziții, Fuziuni, Preluări

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 mai 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 mai 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 mai 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5 mai 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 mai 2026, 22:08 UTC

Câștiguri

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 mai 2026, 22:07 UTC

Câștiguri

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:48 UTC

Câștiguri

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 mai 2026, 21:48 UTC

Câștiguri

Pan American Silver 1Q Rev $1.2B >PAAS

5 mai 2026, 21:42 UTC

Câștiguri

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:38 UTC

Câștiguri

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:30 UTC

Câștiguri

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:29 UTC

Câștiguri

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:26 UTC

Câștiguri

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 mai 2026, 21:25 UTC

Câștiguri

Alcon Inc. 1Q EPS 39c >ALC.EB

5 mai 2026, 21:25 UTC

Câștiguri

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 mai 2026, 21:24 UTC

Câștiguri

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:18 UTC

Câștiguri

Mistras Backs 2026 Rev $730M-$750M >MG

5 mai 2026, 21:17 UTC

Câștiguri

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 mai 2026, 21:15 UTC

Câștiguri

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 mai 2026, 21:12 UTC

Câștiguri

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 mai 2026, 21:11 UTC

Câștiguri

SSR Mining 1Q Rev $581.8M >SSRM

5 mai 2026, 21:10 UTC

Câștiguri

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 mai 2026, 21:10 UTC

Câștiguri

SSR Mining 1Q EPS $1.16 >SSRM

5 mai 2026, 21:08 UTC

Câștiguri

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:01 UTC

Câștiguri

Intact Financial 1Q EPS C$4.12 >IFC.T

5 mai 2026, 21:01 UTC

Acțiuni populare

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Comparație

Modificare preț

Fate Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

150% sus

Prognoză pe 12 luni

Medie 4.5 USD 150%

Maxim 7 USD

Minim 2 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruFate Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

4 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 4 analiști care au acordat evaluări ale acțiunilor Fate Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.9101 / 1.14Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

126 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.